9th Annual CAR-TCR Summit
The 9th CAR-TCR Summit is a premier event designed for the cell therapy industry to address key challenges such as manufacturing efficiency, safety, and cost-effectiveness. It offers in-depth insights and networking opportunities for professionals across various stages of cell therapy development, with a focus on discussing and overcoming industry challenges alongside leading experts and academics.
Date: September 17-20, 2024
Location: Hynes Convention Center, Boston, MA
Booth: #60
JOIN US!
Visit Catalent’s Booth (#60) to explore our UpTempo℠ platform process, designed to enhance the efficiency and scalability of your cell therapy manufacturing processes.
Engage with our experts to learn how Catalent’s innovative solutions can improve safety, reduce costs, and accelerate product release times for your cell therapy pipelines. Complete the form to schedule a meeting with Catalent Cell Therapy experts at the 9th Annual CAR-TCR Summit!
FEATURED SPEAKING SESSION
Title: Decentralized Manufacturing Leveraging Platform Innovation and Commercialization for CAR-T and TCR-T Therapy
Date: September 18, 2024
Time: 11:05-11:15 am EDT
Key Learning Points:
- Autologous Cell Therapy Product: UpTempo℠ Autologous CAR-T Platform – Advanced GMP compliant CAR-T workflow
- Allogeneic Cell Therapy Product: iPSC Platform – 1] GMP compliant iPSC lines 2] iPSC derived cell therapy differentiation protocols
- CAR-T and TCR-T Therapy Analytical QC Package
SPEAKER
Junxia Wang, Ph.D.
Senior Director
Product Development
Catalent Cell Therapy
ABOUT CATALENT CELL & GENE THERAPY
Catalent Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies and viral vaccines, Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, and oncolytic viruses. As an experienced and innovative partner, it has a global network of dedicated, development, clinical, and commercial manufacturing facilities, including an EMA- and FDA-licensed viral vector facility, and fill/finish capabilities located in the U.S. and Europe. With integrated solutions for plasmid DNA, viral vectors, and autologous and allogeneic cell therapies through clinical trial packaging and logistics, Catalent can provide full supply chain control, helping innovators get their advanced therapies to patients, faster.
